Catalog No.S1177

PD98059 Chemical Structure

Molecular Weight(MW): 267.28

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 470 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 49 Publications

10 Customer Reviews

  • a-c, Inhibitors of BRAFV600E (PLX4032) and MEK1/2 (PD98059 or AZD6244) increase PGC1α and ID2 expression (a, b) and repress integrin expression and signalling (b, c). Cells were treated with indicated concentration of inhibitors for 6 h (a, b) or 24 h (c). d, e, PLX4032 increases the interaction between ID2 and TCF4 (d) and decreases the occupancy of TCF4 at the promoters of integrin genes (e). f–g, PGC1α and ID2 are partially required for PLX4032-mediated inhibition of invasion and metastasis. For in vitro assays (f), A375 cells were incubated with 1 μM PLX4032 for 10 h. Images represent one picture captured per membrane with the scale bar representing 200 μm. Values in a, b, e and f represent mean±s.d. of independent biological triplicates; *P<0.05 and **P<0.01 by Student's t-test  in a, b, e, f.

    Nature, 2016, 537(7620):422-427.. PD98059 purchased from Selleck.


    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD98059 purchased from Selleck.


    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD98059 purchased from Selleck.

    effect of ERK1/2 inhibitor PD98059 (1, 5, and 10 μM) on SRP72 protein expression was evaluated on Jurkat cells stimulated with rhIL-1. The cells were harvested at 0,120, and 240 min, and the protein expression was verified by WB using antibodies against human SRP72, human SRP54 (nonphosphorylated SRP protein), and humanGAPDHas constitutive protein.Adecreased SRP72 expression at 10 μM and 240 min was found.



    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.

  • C, effect of ERK1/2 inhibitor PD98059 (1, 5, and 10 μM) was evaluated in SRP72-immunoprecipitated cell lysates. WB using anti-phosphoserine antibody showed a decreased SRP72 band when used as the inhibitor at concentrations of 1 μM at 240 min, 5 μM at 120 min, and 10 μM at 120 and 240 min (lanes 3, 5, 8, and 9). D, results were analyzed and RUA illustrated, finding significant results at 1 μM at 240 versus 0, 5 μM at 120 versus 0, and 10 μM at 120 versus 0 min.



    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.

    We used real time RT-PCR to investigate the effects of PD98059 on SRP72 mRNA expression. All the samples were treated under the same experimental conditions used in protein tests done by WB, and phosphorylation was measured indirectly by IP-WB. The results did not show significant changes on the mRNA expression of SRP72 after the treatment with these inhibitors.



    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.


    Activation of a TLR2eERK1/2 pathway in MDDC. (C) MDDC were either untreated or treated with C. pneumoniae alone or in the presence of the ERK1/2 inhibitor PD98059 for 48 h. IL-12p70 and IL-10 release in culture media was assessed by ELISA. (D) MDDC were treated as in panel C for 48 h and then cocultured with purified allogeneic CD3t T cells. On day 12, supernatants were collected, and secreted cytokines were measured by ELISA.

    Microbes Infect 2013 15, 105-14. PD98059 purchased from Selleck.

    HepG2 cells, “Pnt-2” primary HCC cells or THLE-2 normal liver cells were pretreated with PD-98059 (1 mM) or MEK-162 (“MEK”, 1 mM) for 1 h prior toWAY-600 (“WAY”, 100 nM) treatment, after applied period, cell viability and apoptosis were tested by MTT assay (F and H).

    Biochem Biophys Res Commun, 2016, 474(2):330-7.. PD98059 purchased from Selleck.

  • Collagen I and α-SMA are conducive for S. aureus adhesion to and invasion into BMFBs. BMFBs were treated with PD98059 2 h before the addition of 5 ng/ml TGF-β1; 24 h later, the adhesion (A) and invasion (B) assays were performed as previously described. The results are expressed as the mean cfu/ml ± SD from experiments performed in triplicate (*P < 0.05, **P < 0.01).

    Microb Pathog, 2017, 106:25-29. PD98059 purchased from Selleck.

    After starved in serum-free medium for 24h,T47D cells incubated with the indicated concentrations of  PD98059 for 3h,followed by 20-minute  stimolation of 100ng/ml EGF.


    2010 Dr. Zhang of Tianjin Medical University. PD98059 purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.
Features Does not inhibit c-Raf phosphorylated MEK1.
MEK1 [1]
(Cell-free assay)
2 μM
In vitro

PD98059 inhibits either basal MEK1 or a partially activated MEK produced by mutation of serine at residues 218 and 222 to glutamate (MEK-2E) with IC50 of 2 μM. PD98059 does not inhibit the MAPK homologues JNK and P38. PD98059 is highly selective against MEK, as it does not inhibit a number of other kinase activities including Raf kinase, cAMP-dependent kinase, protein kinase C, v-Src, epidermal growth factor (EGF) receptor kinase, insulin receptor kinase, PDGF receptor kinase, and phosphatidylinositol 3-kinase. PD98059 inhibits PDGF-stimulated activation of MAPK and thymidine incorporation into 3T3 cells with IC50 of ~10 μM and ~7 μM, respectively. [1] PD98059 potently prevents the activation of MEK1 by Raf or MEK kinase with IC50 of 4 μM, and weakly inhibits the activation of MEK2 by Raf with IC50 of 50 μM. PD98059 does not inhibit the activation of MEK homologues MKK4 and RK kinase that participate in stress and interleukin-1-stimulated kinase cascades in KB and PC12 cells, and the activation of p70 S6 kinase by insulin or epidermal growth factor in Swiss 3T3 cells. [2] PD98059 completely blocks the nerve growth factor (NGF)-induced differentiation of PC12 cells without altering cell viability. [3] PD98059 inhibits the proliferation of RAW264.7 cells in the culture containing RANKL in a dose-dependent manner, resulting in an apparent decrease of TRAP-positive cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H1355 NETjZ5RHfW6ldHnvckBCe3OjeR?= MYCyOUDPxE1? Mn3CNUBp MVXicJVvfHNidHjlJGJc[V2SLXnu[JVk\WRiaX7jdoVie2ViaX6gdIhwe3Cqbz3DbIsyKGGwZDDwbI9{eGixLVXST{BmgHC{ZYPzbY9v MVuyOVc3QTF6MR?=
MCF-7  NFfLSIFHfW6ldHnvckBCe3OjeR?= M3rXVlExKM7:TR?= NHzxeWkyKGh? NXG0XFhbcW6qaXLpeJMhUUxvMUit[Y5p[W6lZXSgZ4VtdCCvaXfyZZRqd25? MlvONlU4OjdyMUG=
HepG2  NIiy[WNHfW6ldHnvckBCe3OjeR?= M4DNdlExKM7:TR?= MXG1JIg> M2\WeoJtd2OtczDwbI9{eGixconsZZRm\CCPQWDLd{BqdmS3Y3XkJIJ6KGW6b3flco92eyCWR1[t{tIy MnXqNlU2PjB2OEi=
HepG2  MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYKyNEDPxE1? NHvGXnYzPCCq MUnzeZBxemW|c3XzJHRITi4QskGtbY5lfWOnZDDj[YxtKHC{b3zp[oVz[XSrb36gZY5lKGmwdnHzbY9v MkfJNlU2PjB2OEi=
MDA-MB-231 MoTYSpVv[3Srb36gRZN{[Xl? Mm\2NlUh|ryP M{XD[lIuOyCq NXf6eGtK\GWlcnXhd4V{KHBvRWLLNU8zKGGwZDDTNVAxSTRiZYjwdoV{e2mxbh?= MXSyOVU2PTh5NR?=
SW480 M2jvWGZ2dmO2aX;uJGF{e2G7 M2DzNFIxyqEQvF2= NXPLeIIxOcLiaB?= MmLIdoVlfWOnczD0bIUh\XiycnXzd4lwdiCxZjDBWGY{KHC{b4TlbY4> MUeyOVQ1PzhzNh?=
HCT-15 NEPCNHRHfW6ldHnvckBCe3OjeR?= NIjVXGoyKGh? NEDEVYdifHSnboXheIV{KFCJRUKtbY5lfWOnZDDwbI9{eGixconsZZRqd25ib3[gSZJsyqB? M17tSVI2PDNzNEK1
HCT-15 NXzRWYw2SXCxcITvd4l{KEG|c3H5 MonpNUBp MorKZYJwdGm|aHXzJJRp\SCycn;0[YN1cX[nIHXm[oVkfHNib3[gVGdGOsLiYXfhbY5{fCCldYLjeY1qdi2rbnT1Z4VlKGGyb4D0c5Nqew>? MXOyOVQ{OTR{NR?=
786-O NFfzO2xCeG:ydH;zbZMhSXO|YYm= NF;HTmg2OMLizszN NVnTcYR[OjRiaB?= MkKzdI91\W62aXH0[ZPDqHSqZTDwdo8u[XCxcITveIlkKGWoZnXjeJMhd2ZiTlO= NGPOS4gzPDVyOES3Oi=>
A498 M1LLeWFxd3C2b4Ppd{BCe3OjeR?= NHfDbYY2OMLizszN NX63bHZrOjRiaB?= MlPQdI91\W62aXH0[ZPDqHSqZTDwdo8u[XCxcITveIlkKGWoZnXjeJMhd2ZiTlO= NY\uUnoyOjR3MEi0O|Y>
NHBE MoTsSpVv[3Srb36gRZN{[Xl? NUj1UYlpOi9{MDFOwG0> M1\xdFIhcA>? NEDNcJNifHSnboXheIV{KEmOLUOzJJN1cW23bHH0[YQhS1iFTEivTWwuQCC|ZXPy[ZRqd25? MW[yOFQ4QTV{Nh?=
A375 MV;D[YxtKEmwdnHzbY9vKEG|c3H5 NXPjT2dvOTEkgKOyNEDDvU1? NUDq[GN5OjRiaB?= NELnS2tz\WS3Y3XzJI1mdGGwb33hJINmdGxiaX72ZZNqd25? NYTMb5NPOjR2Nk[wN|Y>
HBMEC M4rubGZ2dmO2aX;uJGF{e2G7 MUKxNEDPxE1? M1fR[|EhcA>? Mlf6Zoxw[2u|IG\FS2YucW6mdXPl[EBGeGiDMjDlfJBz\XO|aX;u Mnv6NlQ1PTh7OEK=
HPAEpiCs  M4OxOWZ2dmO2aX;uJGF{e2G7 NUC0PVJOOzBizszN MkLBNUBp M4j0dYlvcGmkaYTzJHRPTi4QsTDzeIlufWyjdHXkJJA1Oi:yNESgUWFRUyCyaH;zdIhwenmuYYTpc44> NIXYe2gzPDR2MUi3NC=>
BeWo MUTGeY5kfGmxbjDBd5NigQ>? NHX3fFkyOMLizszN NFfnTFUzKGh? M4XZZYlvcGmkaYTzJGVTUzFxMh?= MV:yOFQ{Ozh2Nh?=
PC3  MU\BdI9xfG:|aYOgRZN{[Xl? MnrEOVAh|ryP NH\UXZcxNjViaB?= MX7pcohq[mm2czDNTHkuPDR7LXnu[JVk\WRiYYDvdJRwe2m|wrC= MUmyOFQzPDh6OR?=
MCF-7 M2LVPGZ2dmO2aX;uJGF{e2G7 MUCxNOKh|ryP MljxNVAwOzBibXnu NYD2OlB7emWmdXPld{B1cGViVWTQMYRmeGWwZHXueEBGWkticHjvd5Bpd3K7bHH0bY9v M37Wd|I1OzlyOEG5
HeLa MWfGeY5kfGmxbjDBd5NigQ>? NYizNpBFPTBizszN Mm\DNE42KGh? M13ROYJtd2OtczDUVnguOSCwdXPs[YFzKG2rZ4LheIlwdiCjbnSgWHhPUVBiZH;3ck1z\We3bHH0bY9v MnP0NlQ{PzZ6Mke=
HL-60  NHPQcmhHfW6ldHnvckBCe3OjeR?= MlKzNVAwOjBizszN MoTvNUBp MU\pcohq[mm2czD0bIXDqE5wIHPobY5mdnOrc3X4eJJi[3UEoHnu[JVk\WRiZHnm[oVz\W62aXH0bY9vKGmwdH:g[5JidnWub3P5eIV{ M1nsflI1OzV5MEKw
HL-60 M3TJNGZ2dmO2aX;uJGF{e2G7 MoPqNkDDvU1? MVexOkBp M2LFdmROW09? M37vVolvcGmkaYTzJJRp\SCjc4PvZ4lifGmxbjDv[kBxWzZ{MTDSZYYuOSCjbnSgUmZCXGN|LDDhcoQhfGinIGLBMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJI52[2ynYYKgUmZCXGN| NYHiWlRNOjR|M{CwOlg>
HEK 293 NHTjV3ZHfW6ldHnvckBCe3OjeR?= M3\uS|ExKM7:TR?= M33yWVUhcA>? NXzGSYFOTE2VTx?= MYLpcohq[mm2czDXcpQucW6mdXPl[EDPui2lYYTlcolvN1SFRkSgZYN1cX[rdImgZY5lKG63Y3zlZZIh|rJvY3H0[Y5qdiCjY3P1cZVt[XSrb36= MnrGNlQ{OjR|Nk[=
HEK 293 NXP6[2NkTnWwY4Tpc44hSXO|YYm= NELpPI4yOCEQvF2= NEe2ZY42KGh? MWTEUXNQ M3ToN5N2eHC{ZYPz[ZMhfGinIFPSWEBi[3Srdnn0fS=> MlXhNlQ{OjR|Nk[=
SW480 NVHDV5lITnWwY4Tpc44hSXO|YYm= Mmn3NVAh|ryP MV6yNEBp NHzmOllFVVOR Morrd5VxeHKnc4Pld{B1cGViQ2LUJIFkfGm4aYT5 NVi4[JlmOjR|MkSzOlY>
HCSMCs MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\YTooyOCEQvF2= M{f3clI1KGh? M{W4[4Jtd2OtczDGRWJRPC2rbnT1Z4VlKEiFQWPNR{Bxem:uaX\ldoF1cW:w NH7G[FIzPDNzMkO4NS=>
PANC-1 MlnwSpVv[3Srb36gRZN{[Xl? M2e1RlIxKM7:TR?= MXe0PEBp MnTSbY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[g{rQ3TCCrbjDy[ZNxd26|ZTD0c{B1cGViUGDBVu61yqCjZ3;ubZN1yqB? MX2yOFI6PDF|Mx?=
A549 M3XpXGZ2dmO2aX;uJGF{e2G7 NY\wRVYzOzBizszN MmT2NE42KGh? MnnxSG1UVw>? MX7pcohq[mm2czD0bIUhfGi{b33ibY4ucW6mdXPl[EBKVC16L1PYR2w5NUy3YzDhZ5Rqfmm2eR?= MkOyNlQzPzd4OU[=
A549 M3ruRmZ2dmO2aX;uJGF{e2G7 M4fRclMxKM7:TR?= M1rHZVAvPSCq NUjDSWozTE2VTx?= MnX0bY5pcWKrdIOgeIhzd22kaX6tbY5lfWOnZDDDM2VDWM7{IGTodlI{PcLicHjvd5Bpd3K7bHH0bY9v MYeyOFI4PzZ7Nh?=
Raji  MYTGeY5kfGmxbjDBd5NigQ>? NGLp[IEyOCEQvF2= MV2xJIg> M4PQZ4Jtd2OtczDod2JCTkZiaX7keYNm\CCHcnuxM|IheGixc4Doc5J6dGG2aX;u M2rNflI1OjZ7NkOw
Raji  NFK1NXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHmbZQyOCEQvF2= MWKxJIg> NGD2blFqdmirYnn0d{B1cGViYnHzZYwhd3JiaIPCRWZHNXO2aX31cIF1\WRiY3XscEBxem:uaX\ldoF1cW:wIHHu[EB3cWGkaXzpeJk> NVzpdJluOjR{Nkm2N|A>
HT29 MnjMSpVv[3Srb36gRZN{[Xl? NXq5eWw5OTBizszN NGPzUJozKGh? M4ewdIlvcGmkaYTzJI9nKEqDS{KsJGVTUzFxMjDhcoQhW1SDVEOgdIhwe3Cqb4L5cIF1cW:w Ml\BNlQzPjV{OUO=
HepG2 MV7BdI9xfG:|aYOgRZN{[Xl? NV7wWFFxOjBizszN M{O2OlI1KGh? Mki0bY5pcWKrdIOgSXJMOS9{IIDoc5NxcG:{eXzheIlwdiCjbnSg[Y5p[W6lZYOgWmIyNWmwZIXj[YQh[XCxcITvd4l{ MWiyOFI1PzlyOR?=
HepG2 NIjvNmZHfW6ldHnvckBCe3OjeR?= MYSyNEDPxE1? MW[yJIg> M3PHcIVvcGGwY3XzJHZDOS2rbnT1Z4VlKE[RWF:zZUB1emGwc3PybZB1cW:wYXygZYN1cX[rdIm= NFLKTHAzPDJ2N{mwPS=>
TE4 MYfGeY5kfGmxbjDBd5NigQ>? NXXxUINOOjBxNUCvNVAxKM7:TR?= MXO0PEBp MVrEUXNQ NWLyVFQycW6qaXLpeJMheC2HcnugZY5lKHexcoTtZY5vcW5iZH;3cpJm\3WuYYTl[EBxNUGtdDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M{OyU|I1OjR2MEKz
TE1 M1OxeWZ2dmO2aX;uJGF{e2G7 MXSyNE82OC9zMECg{txO MlvEOFghcA>? MmLkSG1UVw>? Mm\zbY5pcWKrdIOgdE1GemtiYX7kJJdwenSvYX7ubY4h\G:5boLl[5Vt[XSnZDDwMWFsfCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MY[yOFI1PDB{Mx?=
KYSE30 NHn4eJRHfW6ldHnvckBCe3OjeR?= NVvLV|V2OjBxNUCvNVAxKM7:TR?= MojtOFghcA>? MlK2SG1UVw>? NFzWfYJqdmirYnn0d{BxNUW{azDhcoQhf2:{dH3hco5qdiCmb4fudoVofWyjdHXkJJAuSWu2IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NVrBZnZ4OjR{NESwNlM>
TE3 M{C4NmZ2dmO2aX;uJGF{e2G7 MYS1NEDPxE1? M{C0bFQ5KGh? MlvlSG1UVw>? MnLYeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhUEyDIHPsZZN{KEl? MUKyOFI1PDB{Mx?=
TE4 MUXGeY5kfGmxbjDBd5NigQ>? NHmyWVk2OCEQvF2= M3vYSlQ5KGh? M37WTmROW09? NXjDUpZGfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFzBJINt[XO|IFm= NFSzRXIzPDJ2NECyNy=>
TE5 M165[mZ2dmO2aX;uJGF{e2G7 NYraWlFkPTBizszN M3LjV|Q5KGh? MoPESG1UVw>? NUHEenUxfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFzBJINt[XO|IFm= M1PNfVI1OjR2MEKz
KYSE30 MlroSpVv[3Srb36gRZN{[Xl? NV3hWIJuPTBizszN M1;vVlQ5KGh? M2\hdmROW09? M3nRW5VxemWpdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKEiOQTDjcIF{eyCL MXGyOFI1PDB{Mx?=
MKN7 NXrWR3NpTnWwY4Tpc44hSXO|YYm= MXe1NEDPxE1? M13rWFQ5KGh? M3G4e2ROW09? NHv3UGxqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDIUGEuSTB{IH;yJGhNSS2DMkSgcY9t\WO3bHXz NXrFN2dtOjR{NESwNlM>
OE19 Ml;XSpVv[3Srb36gRZN{[Xl? MXi1NEDPxE1? M{fvbFQ5KGh? MWHEUXNQ NXPCN3lJcW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=> MVeyOFI1PDB{Mx?=
KATOIII  M4O2[2Z2dmO2aX;uJGF{e2G7 MnXrOVAh|ryP MmrqOFghcA>? MYHEUXNQ MoXhbY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZiSFzBMWExOiCxcjDIUGEuSTJ2IH3vcIVkfWyncx?= Mm\5NlQzPDRyMkO=
NCI-N87  Ml:2SpVv[3Srb36gRZN{[Xl? Mn;oOVAh|ryP MUC0PEBp NILmPYFFVVOR NYfSV3h4cW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=> NX\sboN[OjR{NESwNlM>
NUGC3 MnPBSpVv[3Srb36gRZN{[Xl? M{PqWlUxKM7:TR?= M1S0bVQ5KGh? MXPEUXNQ MWjpcoNz\WG|ZYOg[ZhxemW|c3nvckBw\iCKTFGtRVAzKG:{IFjMRU1COjRibX;s[YN2dGW| Mmf2NlQzPDRyMkO=
NUGC2 MXjGeY5kfGmxbjDBd5NigQ>? MnS3OVAh|ryP MWS0PEBp NVGze2FMTE2VTx?= MYnpcoNz\WG|ZYOg[ZhxemW|c3nvckBw\iCKTFGtRVAzKG:{IFjMRU1COjRibX;s[YN2dGW| Mmm4NlQzPDRyMkO=
SGC-7901  NYS0eVRnSXCxcITvd4l{KEG|c3H5 MY[yNEDPxE1? MV6yOEBp NIe3XHJqdmirYnn0d{BEWC2vZXTpZZRm\CCjcH;weI9{cXN? MkXVNlQzPDF|NUG=
MG-63 MYfGeY5kfGmxbjDBd5NigQ>? NYj3XGlFOjBizszN NUDBbWhnOC53IHi= NVv5c5l5[myxY3vzJJRp\SCFSD3pcoR2[2WmIIDoc5NxcG:{eXzheIVlKEWOS{GgdJJwfGWrbjDlfJBz\XO|aX;u NWX2Z3dGOjR{M{m2OFA>
ARPE-19 NFS5NYpHfW6ldHnvckBCe3OjeR?= NHixbGUzOCEQvF2= NHXkT|cxNjViaB?= MUfpcohq[mm2czDBdIVtcW5vaX7keYNm\CCyaH;zdIhwenmuYYTpc44hd2ZiRYLrJIFv\CCDa4S= NIHDbJEzPDJ{N{mxPC=>
CRL-2302 NIGwRoRHfW6ldHnvckBCe3OjeR?= NIraU3AzOCEQvF2= MomwNE42KGh? MUDpcohq[mm2czDBdIVtcW5vaX7keYNm\CCyaH;zdIhwenmuYYTpc44hd2ZiRYLrJIFv\CCDa4S= NISzTFEzPDJ{N{mxPC=>
MCF-7 NUPubndGTnWwY4Tpc44hSXO|YYm= NWfYdVRoOjBizszN MXOxJIg> M2HadoFjd2yrc3jld{BmgHC{ZYPzbY9vKG:oIIDoc5NxcG:{eXzheIVlKEWUSzDjc{11emWjdH3lcpQhf2m2aDDjc45rfWejdHW= MnLlNlQzOTZ{OEm=
MCF-7 Mmf4RZBweHSxc3nzJGF{e2G7 MYeyNEDPxE1? NVnvSnpwOSCq MYTpcoNz\WG|ZYOgZ4F{eGG|ZT25JIVvgnmvZTDhZ5Rqfmm2eR?= NV7RfGJ5OjR{MU[yPFk>
DLD-1  NULoZXF[TnWwY4Tpc44hSXO|YYm= MWiyNOKh|ryP MkPxOFghcA>? MnvGdoVlfWOnczD0bIUhSk6LUEOg[ZhxemW|c3nvckBxemVvdILlZZRm\CC5aYToJFUu[XqjLXTD M{f1RVI1OjFzNUix
HT-29 NFPWemRHfW6ldHnvckBCe3OjeR?= NEPpeJYzOMLizszN NFTWbY81QCCq MlfzdoVlfWOnczD0bIUhSk6LUEOg[ZhxemW|c3nvckBxemVvdILlZZRm\CC5aYToJFUu[XqjLXTD M2H1WlI1OjFzNUix
7402 M4TUVWFxd3C2b4Ppd{BCe3OjeR?= M1:wcVMxKM7:TR?= MVe1JIQ> NEjZRmhl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9v MVKyOFIyOTJ3Mx?=
7721 MlXuRZBweHSxc3nzJGF{e2G7 NEfRe3I{OCEQvF2= NX;MbmdzPSCm NX:3PHdV\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdg>? MV2yOFIyOTJ3Mx?=
SGC7901  M2H4fGFxd3C2b4Ppd{BCe3OjeR?= NHLzSYk2OMLizszN MYqyOE81QC95MjDo M1m4R2ROW09? MnLCbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCMQVuyJJNpWk6D MXuyOFE4QDJ2MB?=
SMMC7721 NUfzN5U1TnWwY4Tpc44hSXO|YYm= NGfa[4QzPS93MDFOwG0> M3exc|I1KGh? M2LuRZN2eHC{ZYPz[ZMhfGinIHX4dJJme3Orb36gc4YheC2Da4Sgc5IheC2HUluxM|LDqA>? MUiyOFE3QDB3Nh?=
MCF-7 M1LIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH74NI8yOCEQvF2= NInoOGI1QGh? NIOwWZlFVVOR MlvqdoV3\XK|ZYOgRm5HNWmwZIXj[YQh[2WubDDjfYNt\SCjcoLld5Q> M4W3ZVI1OTZ|NEC0
Caco-2 MYXGeY5kfGmxbjDBd5NigQ>? NFTNR3A2OMLizszN NV7yb5pmPDiq NGDEU2xFVVOR MVPlcohidmOnczD0bIUhdVKQQTDs[ZZmdHNib3dCpHNEVk5zQTzGXHlFOy{EoFzDWEzDqEyRWD|CpGhKTjODLNMgXmcyPi{EoGDESVZCyqCjbnVCpGxISUyVMUdCpIdmdmW|wrDjc{11emWjdHXkJJdqfGhiRHX4 M3XYUVI1OTZzNkm1
HAECs NIXWfJBHfW6ldHnvckBCe3OjeR?= MVmxNEDPxE1? M1XzTFEhcA>? NWLqdnB3yqCjdITlcpVifGW|IGTOSk3PuS2|dHnteYxifGWmIFnDRW0uOSCjbnSgWmNCVS1zIHX4dJJme3Orb36= NYKzUHNmOjRzM{S2OVc>
Ca9-22 M{XhVGZ2dmO2aX;uJGF{e2G7 M175blMh|ryP MnnVNUBp NHPpNmRi[m:uaYPo[ZMhfGinIHHibYxqfHlib3[gTIJTKHSxIHnu[JVk\SCLTD24JJBzd2S3Y4Tpc44> M4\NdlI1OTJ4NUOy
Ca9-22 MYjGeY5kfGmxbjDBd5NigQ>? NIPLe4o{KM7:TR?= NX7OdWt5OS9{IHi= Mn\2doVlfWOnczDIZnIucW6mdXPl[EBCXEZvMjDwbI9{eGixconsZZRqd25? Moe2NlQyOjZ3M{K=
AGS NVHIbnhqTnWwY4Tpc44hSXO|YYm= MorvNVAh|ryPwrC= NVzl[3NoOC53IHi= M2nVZYlvcGmkaYTzJJRp\SC3cILl[5Vt[XSrb36gc4YhfGinIFnMMVgh\2WwZR?= NVfZboVmOjRzME[xOlY>
Caco-2  M{PHeGFxd3C2b4Ppd{BCe3OjeR?= M37PZVExyqEQvF2= MYCyOOKhcA>? MmP1[IVkemWjc3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgOU1HXQ>? MXyyOFA6PTh4Mx?=
HCT-8 NIWwcI1CeG:ydH;zbZMhSXO|YYm= M172fVExyqEQvF2= Mki0NlTDqGh? M2Pmc4Rm[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JFUuTlV? MmTpNlQxQTV6NkO=
A549 Ml36SpVv[3Srb36gRZN{[Xl? NGT3T3g2OMLizszN MUOyJIg> MU\icI9kc3NiRWLLJJBpd3OyaH;yfYxifGmxbjDt[YRq[XSnZDDifUAyNDJvTmG= MnnnNlQxPjd5Mke=
HPMC NETiRnJHfW6ldHnvckBCe3OjeR?= NED4U5YyOMLizszN MkmxOFghcA>? NEHCd2hz\X[ncoPld{B1cGViY3jhcodmeyCrbjDj[YxtKG2xcoDoc4xw\3liaX7keYNm\CCkeTDIS3BFWw>? MkjuNlQxPDJ6M{i=
HPMC MlXxRZBweHSxc3nzJGF{e2G7 M1zaUVExyqEQvF2= NXznc3BGOjUEoHi= MoridoV3\XK|ZYOg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY5lfWOnZDDifUBJT1CGUx?= NXTLcphjOjRyNEK4N|g>
MGC803  NVi2ZWs1SXCxcITvd4l{KEG|c3H5 MonUNlDDqM7:TR?= M4m2OVEhcA>? NVPGenRlcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliSV\OMe6yyqCjbnSgOgKBui2GRmXS NIOwWHgzPDB{N{e1NC=>
SGC7901 MmfiRZBweHSxc3nzJGF{e2G7 NUXBd|J{OjEEoN88US=> M4PSflEhcA>? MoP0bY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhUU[QLd8xxsBidmRiNfMAtk1FTlWU MWOyOFAzPzd3MB?=
COLO205 Ml\jRZBweHSxc3nzJGF{e2G7 MmTKNVAwOjBxNECg{txO NULlZndGOjRiaB?= M2jYWYlv\HWlZYOgSG5CKGyjZHTldkBnd3KvYYTpc44> NVTldpJFOjRyMUmxNFg>
G292  M3WzNWFxd3C2b4Ppd{BCe3OjeR?= MYOzNOKh|ryP MUiyJIg> MnrEdoV{fG:{ZYOgZ4Fxe2GrY3nuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MWCyOFAyOjl|MB?=
BxPC-3 MY\GeY5kfGmxbjDBd5NigQ>? NYLmNYkyOTBizszNxsA> MXi2JIg> NEPuTmxqdmO{ZXHz[UBucVJvMUSzJIV5eHKnc4Ppc44> MXiyN|k4OzdzMB?=
HL-60 M2HYW2Fxd3C2b4Ppd{BCe3OjeR?= NHnxWpA2OMLizszN MkfmNUBp NWrGb3VKemW|Y4Xld{BDSTF2NTDt[YRq[XSnZDDhdI9xfG:|aYO= Mln3NlM6PDh5NUG=
HUVECs MXfGeY5kfGmxbjDBd5NigQ>? NFzBSWozPSEQvF2= NH:0V48yKGh? NGPhPJRqdmO{ZXHz[UBPTi4QulKgdFY2KG63Y3zlZZIhfHKjboPsc4NifGmxbh?= MnjZNlM6ODFyMEi=
LNCaP  MYDGeY5kfGmxbjDBd5NigQ>? NVjkWWNROTBizszNxsA> MVWxJIg> Ml:3[IVkemWjc3XzJJRp\SCHR1[geZBz\We3bHH0[YQheC2\Qj2x NFTHVVUzOzh|OEOxPC=>
HL60  MkHjSpVv[3Srb36gRZN{[Xl? MkTpNlDDqM7:TR?= NUHYVHROPzJiaB?= M13ZW2ROW09? NGL3WZhqdmirYnn0d{Bl[XOjdHnubYIucW6mdXPl[EBETDFzYjDlfJBz\XO|aX;u Ml71NlM5OjV3OEW=
NB4  MWTGeY5kfGmxbjDBd5NigQ>? M{n0XFExKM7:TdMg M3uxWVczKGh? NWXxUZZ4TE2VTx?= Ml;sbY5pcWKrdIOg[IF{[XSrbnniMYlv\HWlZXSgR2QyOWJiZYjwdoV{e2mxbh?= NYnxUZo5OjN6MkW1PFU>
EPOR/CR3 NXnmeY1STnWwY4Tpc44hSXO|YYm= NXzNV5pHPTEEoN88US=> M1:0ZlMhcA>? NFi4c|Nz\WS3Y3XzJGVRVyCjbnSvc5IhUUxvMz3pcoR2[2WmIITo[UB1gXKxc3nu[UBxcG:|cHjvdplt[XSrb39CpC=> M4nDTFI{QDJyN{Ox
HUASMCs M{DjO2Z2dmO2aX;uJGF{e2G7 MkPKNVAh|ryPwrC= MlX1NlQhcA>? NEP3NWVlcW2rbnnzbIV{KEGwZzDJTU1k[XW|ZXSgV29EWzNibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:wwrC= NWjESFd2OjN6MU[0Olg>
HUASMCs MYjGeY5kfGmxbjDBd5NigQ>? NXv6PFFXOTBizszNxsA> NFjLWlMzPCCq NFf5e4RqdmirYnn0d{BCdmdiSVmtbY5lfWOnZDDFVmsyNzJicHjvd5Bpd3K7bHH0bY9vKGyndnXs MVuyN|gyPjR4OB?=
SGC7901 NETXdnVHfW6ldHnvckBCe3OjeR?= NVGydHFoOTBizszNxsA> M2rLPFI1KGh? MmPYbY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRWLLNU8z NYjRU3RbOjN5OUK1PFg>
MKN45 M{TyZ2Z2dmO2aX;uJGF{e2G7 NFrnSFkyOCEQvF5CpC=> NHH2XlUzPCCq NIO1dWRqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBxcG:|cHjvdplt[XSnZDDFVmsyNzJ? MmO4NlM4QTJ3OEi=
SGC7901 Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHH4O2oyOCEQvF5CpC=> NYeyV3ljOjRxNEivO|IhcA>? NGe5XXhqdmirYnn0d{Bk\WyuIHfyc5d1cCClbz30doVifGWmIIfpeIghTEGSVB?= NIfTWWszOzd7MkW4PC=>
MKN45 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\uNVAh|ryPwrC= NH76PY4zPC92OD:3NkBp MXXpcohq[mm2czDj[YxtKGe{b4f0bEBkdy22cnXheIVlKHerdHigSGFRXA>? M4naUFI{Pzl{NUi4
SGC7901 MXvBdI9xfG:|aYOgRZN{[Xl? MV6xNEDPxE4EoB?= NUnueY9xOjRiaB?= MV;pcoNz\WG|ZYOgeIhmKESDUGStbY5lfWOnZDDj[YxtKGGyb4D0c5Nqew>? M3jaVVI{Pzl{NUi4
MKN45 MU\BdI9xfG:|aYOgRZN{[Xl? NGPj[lYyOCEQvF5CpC=> NFuy[pczPCCq MkO4bY5kemWjc3XzJJRp\SCGQWDUMYlv\HWlZXSgZ4VtdCCjcH;weI9{cXN? NEDwTIozOzd7MkW4PC=>
BxPC-3 cells M2G2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILMUWwzOMLizszN M{LQZlAvPSCq NGqwNFRqdmirYnn0d{BXTUeILVGtdoVofWyjdHXkJGhWXkWFIHfyc5d1cCCjbnSgeJVj\SCob4LtZZRqd25iaX7keYNm\CCkeTDQRXIuOiCDUB?= MoH3NlM4PjRyNE[=
NB4  M3mxOGFxd3C2b4Ppd{BCe3OjeR?= M4rzcVExNzJyL{[wJO69VQ>? NGTNfFYyNjViaB?= M4WzdmROW09? Ml;y[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHPvMZRz\WG2ZXSge4l1cCCSYXPsbZRigGWu NYiwNlZzOjN5M{W1OFE>
HepG2  NU\xTHFYTnWwY4Tpc44hSXO|YYm= NYXBPJdIOjEEoN88US=> M37k[|I1KGh? MWTpcohq[mm2czD0bIUhUE9vMTDwdo91\WmwIHX4dJJme3Orb36gZ48ufHKnYYTl[EB4cXSqIH3leIZwem2rbh?= M3;5[|I{PzB5NkC5
HUVECs NY\UdIhrSXCxcITvd4l{KEG|c3H5 MW[yM|Qh|ryP MYSyOE81QCCq MW\pcoR2[2W|IHPlcIwh\GWjdHi= NIrueFIzOzdyN{WyNC=>
KG-1  Mn\RRZBweHSxc3nzJGF{e2G7 NEPmVIwzOMLizszN MX[xNkBp Mo\x[Y5p[W6lZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDTNS=> M1zNNlI{PzB4Nkmx
AML 1# MYHBdI9xfG:|aYOgRZN{[Xl? NWTjRot5OjEEoN88US=> MnrCNVIhcA>? MVnlcohidmOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IGOx NHH0UZIzOzdyNk[5NS=>
A2780  MWrGeY5kfGmxbjDBd5NigQ>? NIrDNHUzOMLizszN MYCxJIg> Ml7kZoxw[2u|IFTUR2QucW6mdXPl[EBFWjViZYjwdoV{e2mxbh?= M3fYVFI{Pjl4OE[y

... Click to View More Cell Line Experimental Data

In vivo Treatment of mice 30 minutes before focal cerebral ischemia with PD98059 protects against damage, resulting in a decrease in infarct volume. [5] Pretreated with PD98059 (10 mg/kg per i.v. injection) 30 minutes before and then together with hourly cerulein injections for 3 hours significantly ameliorates cerulein-induced acute pancreatitis ipancreatitis on the basis of pancreatic wet weight and histology. [6] Administration of PD98059 (10 mg/kg) in mice 1 hour after carrageenan causes a reduction in all the parameters of inflammation measured. [7]


Kinase Assay:


+ Expand

In vitro MEK-inhibitory activity:

Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50 μL of 50 mM Tris, pH 7.4/10 mM MgCl2/2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE.
Cell Research:


+ Expand
  • Cell lines: K-Balb, KNRK, v-raf-3Y1, SRA/3Y1, EGFR/3T3, and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 3 dyas, or 7-10 days
  • Method:

    For monolayer growth, cells are plated into multi-well plates at 10,000-20,000/mL. Forty-eight hours later, various concentrations of PD98059 are added to the cell growth medium and incubation is continued for an additional 3 days. Cells are then removed from the wells by incubation with trypsin and enumerated with a Coulter Counter. For growth in soft agar, cells are seeded into 35-mm dishes at 5,000-10,000 cells per dish with growth medium containing 0.3% agar and desired concentrations of PD98059. After 7-10 days of growth, visible colonies are manually enumerated with the aid of a dissecting microscope.

    (Only for Reference)
Animal Research:


+ Expand
  • Animal Models: Male Sprague–Dawley rats with acute pancreatitis
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 10 mg/kg
  • Administration: Injection i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL warmed (52.37 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 267.28


CAS No. 167869-21-8
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to formulate this inhibitor for i.p. injection?

  • Answer:

    You can prepare the stock by the vehicle 30% PEG400/0.5% Tween80/5% Propylene glycol, 0.5% CMC.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Tags: buy PD98059 | PD98059 supplier | purchase PD98059 | PD98059 cost | PD98059 manufacturer | order PD98059 | PD98059 distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID